Biological agents for severe asthma: the evolution of the at-home self-injection approach. Issue 4 (August 2020)

• Record Type: Journal Article
• Authors: Lombardi, Carlo; Bagnasco, Diego; Passalacqua, Giovanni
• Is Part Of: Current opinion in allergy and clinical immunology. Volume 20:Issue 4(2020:Aug.)
• Publication Date: 2020-08
• Subjects: autoinjector -- biological treatment -- prefilled syringe -- self-management -- severe asthma; Allergy -- Periodicals; Clinical immunology -- Periodicals; Hypersensitivity; Immunity; Immune System Diseases; Allergy and Immunology; 616.079
• DOI: 10.1097/ACI.0000000000000656
• Languages: English
• ISSNs: 1528-4050

Abstract

Abstract : Purpose of review: New biological agents, in addition to the well-established omalizumab, have been nowadays introduced into clinical practice for severe asthma. This suggested the possibility of an at-home self-administration, as currently happening for other biological agents for immune-mediated diseases. Recent findings: In the very recent years, there were structured clinical trials investigating the self at home administrations of biologicals for severe asthma, showing with different principles, a possible advantage and convenience for the patient, and a socioeconomic saving. Summary: The literature analysis currently shows that the at-home self-administration of biologicals for severe asthma is a promising approach to improve the treatment of such disease.